Jenken Biosciences, Inc., a specialty pharmaceutical company located in Research Triangle Park, NC, is developing drugs that modulate cytokine release involved in chronic inflammation-associated organ damage, a >$10B worldwide market. Our current focus within this broad opportunity is chronic inflammatory liver disease which includes chronic hepatitis, cirrhosis and non-alcoholic steatohepatitis (NASH).

The Company’s drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs and their analogs or metabolites which possess favorable toxicological, pharmacokinetic and effectiveness profiles.